Lesinurad/allopurinol
| Combination of | |
|---|---|
| Lesinurad | urate transporter inhibitor |
| Allopurinol | xanthine oxidase inhibitor |
| Clinical data | |
| Trade names | Duzallo |
| AHFS/Drugs.com | Professional Drug Facts |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Lesinurad/allopurinol (trade name Duzallo) is a fixed-dose combination drug for the treatment of gout.[1] It contains 200 mg of lesinurad and 300 mg of allopurinol. In August 2017, the US Food and Drug Administration approved it for the treatment of hyperuricemia associated with gout in patients for whom target serum uric acid levels have not been achieved with allopurinol alone.[2] It was approved for medical use in the European Union in August 2018.[3] In February 2019, it was discontinued by its manufacturer for business reasons and is no longer available.[4][5][3]
References
[edit]- ^ Skidmore-Roth L (2020). Mosby's 2020 Nursing Drug Reference (33rd ed.). St. Louis, Missouri: Elsevier Health Sciences. p. e1. ISBN 978-0-323-67465-2.
- ^ "FDA Clears First Fixed-Dose Combination Treatment for Gout". Medscape. August 21, 2017.
- ^ a b "Duzallo EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 19 August 2020.
- ^ "Duzallo and Zurampic". Ironwood Pharmaceuticals. Archived from the original on 10 August 2020. Retrieved 31 July 2020.
- ^ "Withdrawal Zurampic and Duzallo". Grunenthal. 13 January 2019. Retrieved 19 August 2020.
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |